Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis

• Published in: Journal of headache and pain Vol. 21; no. 1; pp. 66 - 12
• Main Authors: Hou, Min, Xing, Haiyan, Li, Chen, Wang, Xianfeng, Deng, Dongmei, Li, Juan, Zhang, Pan, Chen, Jianhong
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 05.06.2020; Springer Nature B.V; BMC
• Subjects: 5-HT1F receptor agonist; Agonists; Central nervous system; Clinical trials; Fatigue; Headache; Internal Medicine; Lasmiditan; Medicine; Medicine & Public Health; Meta-analysis; Migraine; Nausea; Neurology; Pain; Pain Medicine; Research Article; Safety; Serotonin S1 receptors; Systematic review; Lasmiditan; 5-HT; receptor agonist; Migraine; Meta-analysis

Background Migraine has been recognized as one of common diseases in the world whose current treatment options are not ideal. Lasmiditan, an oral 5-hydroxytryptamine (HT) 1F receptor agonist, appears more promising for the acute treatment of migraine because of considerably better effect profiles wi...